TSHR; | |
MAPK1; | |
HSD17B10; | |
MAPT; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.711E-14 | 1.863E-10 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.795E-14 | 2.029E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.033E-13 | 4.500E-10 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.663E-13 | 1.139E-09 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.161E-13 | 1.733E-09 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.794E-12 | 3.550E-09 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.321E-11 | 4.254E-08 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.214E-11 | 5.098E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.023E-10 | 2.203E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.325E-10 | 6.815E-07 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.512E-10 | 6.815E-07 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 6.403E-09 | 4.497E-06 | CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.193E-08 | 1.291E-05 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 3.538E-07 | 1.712E-04 | CYP2A13, CYP2A6 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 3.515E-07 | 1.712E-04 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.061E-06 | 4.621E-04 | CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.121E-16 | 4.619E-12 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 4.408E-05 | 1.714E-02 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, LMNA |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.227E-12 | 9.225E-11 | CYP2C9, CYP2A6, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.741E-12 | 9.225E-11 | CYP2C9, CYP2A6, CYP2A13, CYP2D6, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.572E-12 | 1.262E-10 | CYP2C9, CYP2A6, CYP2A13, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.750E-09 | 4.637E-08 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.931E-08 | 1.045E-06 | CYP2C9, CYP2A6, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.456E-07 | 7.872E-06 | CYP2C9, CYP2D6, MAPK1, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.731E-05 | 4.944E-04 | CYP2C9, CYP2A6, CYP1A2, CYP2C19, CYP3A4, HSD17B10 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.211E-04 | 1.427E-03 | MAPK1, MAPT, HSD17B10 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 6.117E-04 | 5.403E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 3.366E-04 | 3.568E-03 | CYP2A6, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.354E-04 | 5.160E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.297E-06 | 4.992E-05 | CYP2A6, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |